Actuate Therapeutics Inc (ACTU)
NASDAQ: ACTU
· Real-Time Price · USD
7.59
-0.18 (-2.32%)
At close: Jun 18, 2025, 10:05 AM
-2.32% (1D)
| Bid | 7.5 |
| Market Cap | 149.01M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -25.31M |
| EPS (ttm) | -3.15 |
| PE Ratio (ttm) | -2.41 |
| Forward PE | -6.36 |
| Analyst | Buy |
| Ask | 7.69 |
| Volume | 1,927 |
| Avg. Volume (20D) | 59,998 |
| Open | 7.82 |
| Previous Close | 7.77 |
| Day's Range | 7.59 - 7.94 |
| 52-Week Range | 5.51 - 11.99 |
| Beta | 1.69 |
About ACTU
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ACTU
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ACTU stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-11.01%
Actuate Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
1 month ago
-6.88%
ACTU stock has given up its prior gain. Actuate Therapeutics shares were trading higher after the company announced elraglusib combined with GnP met its primary endpoint in its ongoing Phase 2 trial.